Baird Reiterates a 'Neutral' on Alexion Pharmaceuticals (ALXN); Raising Estimates and Target Again
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Baird reiterates a 'Neutral' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target raised to $67.00.
Baird analyst says, "Raising Soliris estimates - again - following ALXN's latest guidance raise. With management's well-established track record of conservative guidance, we think near-term upside to expectations should be presupposed, and continue to model above consensus. Based on this potential, we're raising our price target to $67, but continue to think upside is largely priced in here in the high $60s. Still waiting for a pullback as an opportunity to get more involved, and see a better entry point in the mid-$50s."
"...As such, raising RWB FY11-FY14 Soliris estimates to $770M, $1040M, $1290M, and $1548M, respectively, which remain above consensus ($762M, $1003M, $1254M, and $1492M)."
For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $66.18 yesterday.
Baird analyst says, "Raising Soliris estimates - again - following ALXN's latest guidance raise. With management's well-established track record of conservative guidance, we think near-term upside to expectations should be presupposed, and continue to model above consensus. Based on this potential, we're raising our price target to $67, but continue to think upside is largely priced in here in the high $60s. Still waiting for a pullback as an opportunity to get more involved, and see a better entry point in the mid-$50s."
"...As such, raising RWB FY11-FY14 Soliris estimates to $770M, $1040M, $1290M, and $1548M, respectively, which remain above consensus ($762M, $1003M, $1254M, and $1492M)."
For more ratings news on Alexion Pharmaceuticals click here and for the rating history of Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $66.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
